RBC Capital Maintains Outperform on Nuvation Bio, Lowers Price Target to $17
Benzinga Newsdesk 5 hours ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Leonid Timashev maintains Nuvation Bio (NYSE:NUVB) with a Outperform and lowers the price target from $20 to $17.
RBC Capital analyst Leonid Timashev maintains Nuvation Bio (NYSE:NUVB) with a Outperform and lowers the price target from $20 to $17.